Cargando…

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia

We have developed a deep-scale proteome and phosphoproteome database from 44 representative acute myeloid leukemia (AML) patients from the LAML TCGA dataset and 6 healthy bone marrow–derived controls. After confirming data quality, we orthogonally validated several previously undescribed features of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kramer, Michael H., Zhang, Qiang, Sprung, Robert, Day, Ryan B., Erdmann-Gilmore, Petra, Li, Yang, Xu, Ziheng, Helton, Nichole M., George, Daniel R., Mi, Yiling, Westervelt, Peter, Payton, Jacqueline E., Ramakrishnan, Sai M., Miller, Christopher A., Link, Daniel C., DiPersio, John F., Walter, Matthew J., Townsend, R. Reid, Ley, Timothy J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523374/ https://www.ncbi.nlm.nih.gov/pubmed/35895896 http://dx.doi.org/10.1182/blood.2022016033

Ejemplares similares

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
por: Homan, Claire C., et al.
Publicado: (2023)

Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs
por: Asimomitis, Georgios, et al.
Publicado: (2022)

Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
por: Rodriguez-Zabala, Maria, et al.
Publicado: (2023)

Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
por: Stasik, Sebastian, et al.
Publicado: (2022)

Momelotinib is a highly potent inhibitor of FLT3-mutant AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

Repression of TRIM13 by chromatin assembly factor CHAF1B is critical for AML development
por: Dean, Sarai T., et al.
Publicado: (2023)

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
por: Kong, Tim, et al.
Publicado: (2022)

Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias
por: Poplineau, Mathilde, et al.
Publicado: (2022)

Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study
por: Tuyet Kristensen, Daniel, et al.
Publicado: (2023)

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity
por: Mueller, Sarah B., et al.
Publicado: (2022)

Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3A(mut)NPM1(mut) AMLs
por: Donato, Elisa, et al.
Publicado: (2022)

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
por: Bennett, Joshua, et al.
Publicado: (2023)

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

Coping strategies in patients with acute myeloid leukemia
por: Amonoo, Hermioni L., et al.
Publicado: (2022)

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
por: Tahir, Stephen K., et al.
Publicado: (2023)

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
por: Versluis, Jurjen, et al.
Publicado: (2022)

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies
por: Gorak, Edward J., et al.
Publicado: (2023)

Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome
por: Guijarro, Francesca, et al.
Publicado: (2023)

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
por: Lewis, Alexander C., et al.
Publicado: (2022)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
por: Bataller, Alex, et al.
Publicado: (2022)

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses
por: Knudsen, Trine Alma, et al.
Publicado: (2022)

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
por: Niu, Xiaojia, et al.
Publicado: (2021)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021)

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
por: Wakita, Satoshi, et al.
Publicado: (2022)

Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression
por: Stratmann, Svea, et al.
Publicado: (2022)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
por: Zhao, Lianzhong, et al.
Publicado: (2021)

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes
por: Wang, Yu-Hung, et al.
Publicado: (2021)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
por: Goswami, Swagata, et al.
Publicado: (2022)

CAMK2G is identified as a novel therapeutic target for myelofibrosis
por: Miyauchi, Masashi, et al.
Publicado: (2022)

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome
por: Iijima, Mayuko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u5ctok3lsc7hl5ujcd3ga5icps